Cargando…

Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis

BACKGROUND: Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) approved for treating neovascular age-related macular degeneration (nAMD). Multiple treatment regimens are available for treating nAMD. These regimens include manufacturer-recommended regimens, pro re nata (PRN) re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddiqui, Zasim Azhar, Dhumal, Trupti, Patel, Jay, LeMasters, Traci, Almony, Arghavan, Kamal, Khalid M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373014/ https://www.ncbi.nlm.nih.gov/pubmed/36427338 http://dx.doi.org/10.18553/jmcp.2022.28.12.1350

Ejemplares similares

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

Brolucizumab for macular degeneration
Publicado: (2020)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
por: Bae, Ki Woong, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis
por: Almony, Arghavan, et al.
Publicado: (2021)

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis
por: Hänsli, Christof, et al.
Publicado: (2023)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry
por: Joshi, Shrinivas, et al.
Publicado: (2023)

Systematic review and meta-analysis of randomized controlled trials of interventions addressing caregiver distress and burden among cancer caregivers
por: Dhumal, Trupti, et al.
Publicado: (2023)

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
por: Zakaria, Nadia, et al.
Publicado: (2022)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
por: Abdin, Alaa Din, et al.
Publicado: (2022)

A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment
por: Holz, Frank G., et al.
Publicado: (2022)

Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
por: Yeom, Hoseok, et al.
Publicado: (2023)

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map
por: Khanani, Arshad M., et al.
Publicado: (2021)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
por: Mehta, Neesurg, et al.
Publicado: (2023)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
por: Zubricky, Ryan, et al.
Publicado: (2023)

Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment
por: Ueji, Natsuki, et al.
Publicado: (2023)

Bilateral blindness after uneventful brolucizumab injection for macular degeneration
por: Barchichat, Ilan, et al.
Publicado: (2022)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis
por: Finger, Robert P., et al.
Publicado: (2022)

Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
por: Mishra, Sanjay Kumar, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
por: Kato, Nobuhiro, et al.
Publicado: (2023)

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
por: Matsumoto, Hidetaka, et al.
Publicado: (2021)

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
por: Gigon, Anthony, et al.
Publicado: (2022)

CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Angermann, Reinhard, et al.
Publicado: (2022)

Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series
por: Zuccarini, Silvio, et al.
Publicado: (2022)

Short-term effect of intravitreal brolucizumab injections in patients with neovascular age-related macular degeneration on retinal nerve fiber layer thickness
por: Jun, Sung Yeon, et al.
Publicado: (2023)

RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence
por: Wykoff, Charles C., et al.
Publicado: (2023)

Morphological Macular Changes Under Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration Refractory to Previous Anti-VEGF Treatment Compared with Treatment-Naive Eyes
por: William, Antony, et al.
Publicado: (2023)

Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study
por: Chakraborty, Debdulal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lqv47spva0q072qshsqtr4lduf